Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Oncoinvent ASA ( (BRRGF) ) is now available.
Oncoinvent ASA’s board has granted CEO Øystein Soug 31,884 share options under its long-term incentive program at a strike price aligned with the recent volume-weighted average share price, bringing his total holdings to 10,576 shares and 92,949 options. The options vest over several years with a one-year cliff and a seven-year expiry, underscoring the company’s use of equity-based incentives to retain key leadership and align management with shareholders as it advances its lead radiopharmaceutical candidate through clinical development.
The board maintains that the option program’s structure and size are in line with market practice among comparable peers, positioning Oncoinvent competitively in attracting and retaining specialized talent in oncology drug development. This move may reassure investors about leadership stability at a time when the company is pursuing scale-up and potential commercialization of Radspherin, a therapy with blockbuster ambitions and growing support from clinicians and industry partners.
Data from phase 1 and phase 1/2a trials in ovarian and colorectal cancers indicate an excellent safety profile and promising efficacy signals for Radspherin, bolstering confidence in its potential to become a new standard of care in post-surgical cancer treatment. With interim data from a randomized phase 2 ovarian cancer trial expected in 2026 and a cost-effective manufacturing model, Oncoinvent is positioning itself for broader market impact in cancers that spread to the peritoneum and for sustained commercial growth.
More about Oncoinvent ASA
Oncoinvent ASA is a Norwegian radiopharmaceutical company developing Radspherin, a receptor-independent alpha radiation therapy targeting residual micrometastases in the abdominal cavity. The lead program focuses on preventing or delaying peritoneal recurrence in ovarian and colorectal cancer after surgery, aiming to extend disease-free survival with a simple, scalable product that integrates into existing surgical workflows and has shown promising early clinical data.
Average Trading Volume: 14,496
Current Market Cap: NOK204.5M
See more insights into BRRGF stock on TipRanks’ Stock Analysis page.